Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6899
Gene Symbol: TBX1
TBX1
0.100 Biomarker group BEFREE In cases of d-TGA, the FINE method has a high success rate in generating 3 specific abnormal cardiac views and therefore can be performed to screen for this congenital defect. 31675129 2020
Entrez Id: 1717
Gene Symbol: DHCR7
DHCR7
0.100 Biomarker group BEFREE The case with bilateral renal agenesis presented a novel combination of a null allele and a putative C-terminus missense mutation in the DHCR7 gene CONCLUSIONS: In view of the discrepancy between the prevalence of SLOS among newborns and the carrier frequency of a heterozygous DHCR7 gene mutation, the syndrome-specific internal malformation pattern may be helpful not to miss SLOS diagnosis in fetuses at prenatal ultrasound and fetal autopsy. 31840946 2020
Entrez Id: 6657
Gene Symbol: SOX2
SOX2
0.090 GeneticVariation group BEFREE Mutations in the key transcription factor, SOX2, alone account for 20% of anophthalmia (no eye) and microphthalmia (small eye) birth defects in humans - yet its regulation is not well understood, especially on the post-transcription level. 31814023 2020
Entrez Id: 90
Gene Symbol: ACVR1
ACVR1
0.080 GeneticVariation group BEFREE We analyzed baseline whole body (minus skull) computed tomographic (CT) scans of 113 individuals with classic clinical features of FOP and the ACVR1 (R206H) mutation who were enrolled in a non-interventional natural history study ((NCT02322255)) for skeletal malformations, atypical morphology, intra-articular synovial osteochondromatosis, developmental arthropathy, and associated degenerative joint phenotypes. 31655222 2020
Entrez Id: 10370
Gene Symbol: CITED2
CITED2
0.080 GeneticVariation group BEFREE Gene mutations in CITED2 lead to a series of cardiac malformations and congenital heart defects (CHD). 31515672 2020
Entrez Id: 8085
Gene Symbol: KMT2D
KMT2D
0.080 Biomarker group BEFREE Using the Xenopus model system we find that Kmt2d loss-of-function recapitulates major features of Kabuki syndrome including severe craniofacial malformations. 31813957 2020
Entrez Id: 6926
Gene Symbol: TBX3
TBX3
0.080 GeneticVariation group BEFREE Indeed, mutations in the human TBX3 lead to ulnar mammary syndrome which is characterized by several clinical malformations including hypoplasia of the mammary and apocrine glands, defects of the upper limb, areola, dental structures, heart and genitalia. 31669645 2020
Entrez Id: 5172
Gene Symbol: SLC26A4
SLC26A4
0.070 GeneticVariation group BEFREE All subjects except for two in the SLC26A4 group had concurrent Mondini malformation and enlarged vestibular aqueduct. 31124793 2020
Entrez Id: 2706
Gene Symbol: GJB2
GJB2
0.040 GeneticVariation group BEFREE Patients with GJB2 mutations appeared to have better functional status of the auditory nerve than patients with SLC26A4 mutations who had concurrent Mondini malformation and enlarged vestibular aqueduct and patients with idiopathic hearing loss. 31124793 2020
Entrez Id: 8239
Gene Symbol: USP9X
USP9X
0.030 GeneticVariation group BEFREE USP9X escapes X inactivation, and in female subjects de novo heterozygous copy number loss or truncating mutations cause haploinsufficiency culminating in a recognizable syndrome with intellectual disability and signature brain and congenital abnormalities. 31443933 2020
Entrez Id: 2200
Gene Symbol: FBN1
FBN1
0.030 GeneticVariation group BEFREE Fibrillin-1 (FBN1) mutations cause connective tissue dysgenesis the main ocular manifestation being ectopia lentis (EL), which may be syndromic or non-syndromic. 31527767 2020
Entrez Id: 2022
Gene Symbol: ENG
ENG
0.030 Biomarker group BEFREE Depletion in endoglin may lead to the formation of vessel malformations in the presence of angiogenic stimuli. 31841722 2020
Entrez Id: 196
Gene Symbol: AHR
AHR
0.030 Biomarker group BEFREE Our results showed that the AHR inhibitor, CH223191 (CH) as well as the ROS scavenger, N-Acetyl-L-cysteine (NAC), significantly mitigated the PM2.5-induced cardiac malformations in zebrafish embryos. 31837856 2020
Entrez Id: 3320
Gene Symbol: HSP90AA1
HSP90AA1
0.020 Biomarker group BEFREE However, at the level of the individual, this mechanism can result in simultaneous expression of deleterious variants as well as reduced activity of a variety of Hsp90 chaperoned pathways and potentially shift phenotypic variability over the disease threshold resulting in birth defects. 31821846 2020
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.020 GeneticVariation group BEFREE These results suggest that BRCA and MMR genes play an important role in human embryogenesis and that if their function is lowered because of heterozygote mutations, congenital malformations are either more likely (BRCA1 mutations) and/or more susceptible to concern several anatomical systems. 30785647 2020
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.020 Biomarker group BEFREE Frequencies of malformation in BRCA2 and MMR mutated families were similar to families without a cancer syndrome. 30785647 2020
Entrez Id: 145282
Gene Symbol: MIPOL1
MIPOL1
0.010 Biomarker group BEFREE Mirror Image Polydactyly 1 (MIPOL1) is generally associated with congenital anomalies. 31609475 2020
Entrez Id: 84172
Gene Symbol: POLR1B
POLR1B
0.010 Biomarker group BEFREE Pathogenic variants in the RNA polymerase I subunit POLR1B might induce massive p53-dependent apoptosis in a restricted neuroepithelium area, altering NCC migration and causing cranioskeletal malformations. 31649276 2020
Entrez Id: 3166
Gene Symbol: HMX1
HMX1
0.010 GeneticVariation group BEFREE The strongest significant SNP was identified on OAR6, approximating the evolutionarily conserved region of the HMX1 gene, which is related to congenital malformations of the external ear in other species such as cattle and rats. 31691317 2020
Entrez Id: 3692
Gene Symbol: EIF6
EIF6
0.010 Biomarker group BEFREE The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study, RESULTS: We included 194 women with a mean age of 31 (17-45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. 31728906 2020
Entrez Id: 57492
Gene Symbol: ARID1B
ARID1B
0.010 GeneticVariation group BEFREE ARID1B gene mutations have been associated with two hereditary syndromic conditions, namely Coffin-Siris (CSS, MIM#135900) and Nicolaides-Baraitser syndromes (NCBRS, MIM#601358), characterized by neurodevelopment delay, craniofacial dysmorphisms and skeletal anomalies. 31421289 2020
Entrez Id: 56654
Gene Symbol: NPDC1
NPDC1
0.010 Biomarker group BEFREE The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study, RESULTS: We included 194 women with a mean age of 31 (17-45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. 31728906 2020
Entrez Id: 57178
Gene Symbol: ZMIZ1
ZMIZ1
0.010 Biomarker group BEFREE ZMIZ1, zinc finger MIZ-domain containing 1, has recently been described in association with syndromic intellectual disability in which the primary phenotypic features include intellectual disability/developmental delay, seizures, hearing loss, behavioral issues, failure to thrive, and various congenital malformations. 31833199 2020
Entrez Id: 3982
Gene Symbol: LIM2
LIM2
0.010 AlteredExpression group BEFREE High levels of MPs (20 and 200 μg/L) decreased the hatchability, delayed the hatching time, and suppressed the growth, whereas Phe inhibited hatching and caused malformations in larvae. 31759759 2020
Entrez Id: 759
Gene Symbol: CA1
CA1
0.010 Biomarker group BEFREE The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study, RESULTS: We included 194 women with a mean age of 31 (17-45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. 31728906 2020